//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Welcome to The Lancet, one of the world’s leading medical journals, published weekly since 1823. 🌐 thelancet.com
The Lancet









Loading...
Foodborne illnesses caused 1.5 million deaths and cost US$647 billion in economic losses in 2021, new analysis estimates in @lancetgh.bsky.social Read now 👉 spkl.io/633257Bk5V
📖 Explore the full issue: tinyurl.com/yt8nkd3h
Who's really in the loop? Rethinking oversight in AI-assisted health care 🔗 spkl.io/633277BQYt
Ebola is testing global health—again A growing outbreak in DR Congo & Uganda is exposing: - Fragile health systems - Gaps in preparedness - Risks to health-care workers And there is still no licensed vaccine for this strain. Find out more: spkl.io/633237Bv4v
Presented today at #ERA2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death. Explore the research: spkl.io/633287Badg
Behind every paper at The Lancet Group are layers of editorial scrutiny and integrity checks. ✅ Learn how we work with authors and teams around the world to support trustworthy research: spkl.io/6332576U3b
Presented today at #ERA2026 ⤵️ Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial 🔗 spkl.io/633257BZOL
An immunotherapy warrants further investigation as a treatment for severe #hantavirus pulmonary syndrome, early evidence from 10 patients suggests. Find out more in @thelancetinfdis.bsky.social spkl.io/633217Bkbc
🆕 Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson’s disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study spkl.io/6332076Ohi
4d
5d
Chronic kidney disease (#CKD) affects 788–844 million adults worldwide — and is projected to become the fifth leading cause of death by 2040. A new Series, presented today at #ERA2026, examines what is needed to change this trajectory: spkl.io/63321765k5
3d
5d
5d
6d
6d
7d
7d
7d
Explore the current issue of The Lancet, a world leading medical journal published weekly since 1823
tinyurl.com
The Lancet, 06 June 2026, Volume 407, Issue 10545, Pages 2263-2344
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet